{
  "id": "047acd0c-5781-435a-95c9-481b8ca6f5bf",
  "title": "Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans",
  "link": "https://www.nature.com/articles/s41586-025-09355-7",
  "description": "",
  "author": "Uğur Şahin",
  "published": "2025-07-16",
  "source": "https://www.nature.com/nature.rss",
  "categories": null,
  "byline": "Türeci, Özlem",
  "length": 7535,
  "excerpt": "Nature - Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans",
  "siteName": "Nature",
  "favicon": "https://www.nature.com/static/images/favicons/nature/apple-touch-icon-f39cb19454.png",
  "text": "Correction to: Nature https://doi.org/10.1038/s41586-021-03653-6 Published online 27 May 2021In this article, we reported that some participants exhibited pre-existing CD4+ and CD8+ T-cell responses against the C-terminal part of the SARS-CoV-2 spike protein. However, we have discovered that the apparent pre-existing responses were actually responses against a contamination of two of the four lots of the spike protein sub-pool 2 (S pool 2, covering the C-terminal part of the spike protein) originating from the manufacturer, which were used in several assays. We identified the contaminating peptide in these two lots and have corrected some figures to remove the affected S pool 2 data. Removing these data affects only those statements relating to pre-existing T-cell responses, which we have now also removed from the manuscript. The contamination did not directly affect S pool 1 data. The overall results and conclusions remain the same.Since baseline responses to S pool 2 were measured using contaminated lots, we assumed that positive responses were due to the contaminating peptide. Therefore, we have now reanalyzed the data and excluded all data points for participants meeting the following two criteria: (1) their samples were analyzed with one of the contaminated lots of S Pool 2 and (2) their baseline response was positive. As only a fraction of S pool 2 data was actually removed, the overall results and conclusions remain the same.In Fig. 2 data describing the magnitude of T-cell responses, 9 of 37 participants were removed from the S pool 2 analysis in panels 2a and 2b of the revised figures. For panel 2a, this altered the number of vaccine responders shown for each dose group, but the noted poly-epitopic CD4+ T-cell responses are still apparent. Panel 2b shows the magnitude of responses with combined S pool 1 and S pool 2 data and the data points (11 for CD4+ T cells and 15 for CD8+ T cells) corresponding to the S pool 2 data for the 9 participants were removed. Two of 6 participants were removed from the CD8+ T-cell spot counts from the 30 µg data in panel 2c. The response numbers in the revised Fig. 2c remain unchanged as these are combined S pool 1 and S pool 2 responses.Within the cytokine polarization data in Fig. 3, the lower portion of panel 3a corresponding to S pool 2 data was revised as we excluded 1 participant from the 20 µg dose cohort due to non-specific responses to the S pool 2 peptide lot in this experiment. Remaining data and conclusions in the revised figure remain unchanged.In the revised Extended Data Fig. 5, data from 9 of 37 participants were also removed from panel 5b as this corresponds to the data in Fig. 2. The response values remain unchanged in the revised figure as they take into account the combined S pool 1 and S pool 2 responses.We updated the pie chart in Extended Data Fig. 5d to remove 2 data points from the “S pool 1 \u0026 2” category and 1 from the “S pool 1 only” category for CD4+ T cells. For the CD8+ T-cell chart, we removed 6 data points from the “S pool 1 only” category and 1 data point from “None”. Overall, samples from “S pool 1 only” were removed because without reliable S pool 2 data for these participants, we could not conclusively assign responses to “S pool 1 only” versus “S pool 1 \u0026 2”.We fully removed panel 5e from Extended Data Fig. 5 as it was based on what were previously considered pre-existing responses to S pool 2. Since we now know these are non-specific responses due to the contamination, the panel has been removed.For Extended Data Fig. 5, panel 5f (now 5e), we previously chose ELISpot examples that were from participants with a non-specific response to S pool 2. We have updated the revised figure to show a single example from a participant that had no such response.Three panels within Extended Data Fig. 7 were revised: 7b, 7d and 7e. In panel 7b exploring the CD4+ T-cell profiles, we removed 1 participant in the 20 µg dose group due to the non-specific response to S pool 2. In panel 7d, we removed data for 10 of 41 participants that showed non-specific CD8+ T-cell responses to S pool 2. The values above the data points were also updated as these correspond to the mean fractions per dose cohort and were thus affected by the data removal. In the revised panel 7e, we removed data from 3 of 8 participants in the CD8+ responses against S pool 2. The overall response kinetics shown in this figure remain unchanged.The figures have been updated. Text in Figs. 2, 3 and Extended Data Figs. 5, 7 legends were updated, and the “Vaccine-induced T cell responses” and “Polarization of T cell responses” sections have been updated, while the fourth paragraph of the original Discussion (and citations to original refs. 35,36) has been removed. For comparison, the original figure panels are available as Supplementary Information alongside the online version of this amendment. The changes have been made to the HTML and PDF versions of the article. Author informationAuthors and AffiliationsBioNTech, Mainz, GermanyUğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz, Mathias Vormehr, Jasmin Quandt, Nicole Bidmon, Alexander Ulges, Daniel Maurus, Sebastian Brachtendorf, Verena Lörks, Julian Sikorski, Peter Koch, Rolf Hilker, Dirk Becker, Ann-Kathrin Eller, Jan Grützner, Manuel Tonigold, Carsten Boesler, Corinna Rosenbaum, Ludwig Heesen, Marie-Cristine Kühnle, Ulrich Luxemburger, Alexandra Kemmer-Brück, David Langer, Stefanie Bolte, Tania Palanche, Azita J. Mahiny, Gábor Boros, Jonas Reinholz, Gábor T. Szabó, Katalin Karikó \u0026 Özlem TüreciTRON gGmbH – Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, GermanyUğur ŞahinRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USAAlina Baum, Kristen E. Pascal \u0026 Christos A. KyratsousBioNTech US, Cambridge, MA, USAAsaf Poran \u0026 Jesse Z. DongBexon Clinical Consulting LLC, Upper Montclair, NJ, USAMartin BexonCRS Clinical Research Services Mannheim GmbH, Mannheim, GermanyArmin SchultzCRS Clinical Research Services Berlin GmbH, Berlin, GermanySybille BaumannUniversity of Texas Medical Branch, Galveston, TX, USAPei-Yong Shi \u0026 Camila Fontes-GarfiasPfizer, Pearl River, NY, USJohn L. Perez, Mark Cutler, David Cooper, Philip R. Dormitzer \u0026 Kathrin U. JansenAuthorsUğur ŞahinAlexander MuikIsabel VoglerEvelyna DerhovanessianLena M. KranzMathias VormehrJasmin QuandtNicole BidmonAlexander UlgesAlina BaumKristen E. PascalDaniel MaurusSebastian BrachtendorfVerena LörksJulian SikorskiPeter KochRolf HilkerDirk BeckerAnn-Kathrin EllerJan GrütznerManuel TonigoldCarsten BoeslerCorinna RosenbaumLudwig HeesenMarie-Cristine KühnleAsaf PoranJesse Z. DongUlrich LuxemburgerAlexandra Kemmer-BrückDavid LangerMartin BexonStefanie BolteTania PalancheArmin SchultzSybille BaumannAzita J. MahinyGábor BorosJonas ReinholzGábor T. SzabóKatalin KarikóPei-Yong ShiCamila Fontes-GarfiasJohn L. PerezMark CutlerDavid CooperChristos A. KyratsousPhilip R. DormitzerKathrin U. JansenÖzlem TüreciCorresponding authorCorrespondence to Uğur Şahin.Supplementary informationRights and permissionsAbout this articleCite this articleŞahin, U., Muik, A., Vogler, I. et al. Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature (2025). https://doi.org/10.1038/s41586-025-09355-7Download citationPublished: 16 July 2025DOI: https://doi.org/10.1038/s41586-025-09355-7",
  "image": "",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv\u003e\n                    \n                        \u003cdiv\u003e\u003cp\u003eCorrection to: \u003ci\u003eNature\u003c/i\u003e \u003ca href=\"https://doi.org/10.1038/s41586-021-03653-6\"\u003ehttps://doi.org/10.1038/s41586-021-03653-6\u003c/a\u003e Published online 27 May 2021\u003c/p\u003e\u003c/div\u003e\u003cp\u003eIn this article, we reported that some participants exhibited pre-existing CD4\u003csup\u003e+\u003c/sup\u003e and CD8\u003csup\u003e+\u003c/sup\u003e T-cell responses against the C-terminal part of the SARS-CoV-2 spike protein. However, we have discovered that the apparent pre-existing responses were actually responses against a contamination of two of the four lots of the spike protein sub-pool 2 (S pool 2, covering the C-terminal part of the spike protein) originating from the manufacturer, which were used in several assays. We identified the contaminating peptide in these two lots and have corrected some figures to remove the affected S pool 2 data. Removing these data affects only those statements relating to pre-existing T-cell responses, which we have now also removed from the manuscript. The contamination did not directly affect S pool 1 data. The overall results and conclusions remain the same.\u003c/p\u003e\u003cp\u003eSince baseline responses to S pool 2 were measured using contaminated lots, we assumed that positive responses were due to the contaminating peptide. Therefore, we have now reanalyzed the data and excluded all data points for participants meeting the following two criteria: (1) their samples were analyzed with one of the contaminated lots of S Pool 2 and (2) their baseline response was positive. As only a fraction of S pool 2 data was actually removed, the overall results and conclusions remain the same.\u003c/p\u003e\u003cp\u003eIn Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e2\u003c/a\u003e data describing the magnitude of T-cell responses, 9 of 37 participants were removed from the S pool 2 analysis in panels 2a and 2b of the revised figures. For panel 2a, this altered the number of vaccine responders shown for each dose group, but the noted poly-epitopic CD4\u003csup\u003e+\u003c/sup\u003e T-cell responses are still apparent. Panel 2b shows the magnitude of responses with combined S pool 1 and S pool 2 data and the data points (11 for CD4\u003csup\u003e+\u003c/sup\u003e T cells and 15 for CD8\u003csup\u003e+\u003c/sup\u003e T cells) corresponding to the S pool 2 data for the 9 participants were removed. Two of 6 participants were removed from the CD8\u003csup\u003e+\u003c/sup\u003e T-cell spot counts from the 30 µg data in panel 2c. The response numbers in the revised Fig. 2c remain unchanged as these are combined S pool 1 and S pool 2 responses.\u003c/p\u003e\u003cp\u003eWithin the cytokine polarization data in Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e3\u003c/a\u003e, the lower portion of panel 3a corresponding to S pool 2 data was revised as we excluded 1 participant from the 20 µg dose cohort due to non-specific responses to the S pool 2 peptide lot in this experiment. Remaining data and conclusions in the revised figure remain unchanged.\u003c/p\u003e\u003cp\u003eIn the revised Extended Data Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e5\u003c/a\u003e, data from 9 of 37 participants were also removed from panel 5b as this corresponds to the data in Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e2\u003c/a\u003e. The response values remain unchanged in the revised figure as they take into account the combined S pool 1 and S pool 2 responses.\u003c/p\u003e\u003cp\u003eWe updated the pie chart in Extended Data Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e5d\u003c/a\u003e to remove 2 data points from the “S pool 1 \u0026amp; 2” category and 1 from the “S pool 1 only” category for CD4\u003csup\u003e+\u003c/sup\u003e T cells. For the CD8\u003csup\u003e+\u003c/sup\u003e T-cell chart, we removed 6 data points from the “S pool 1 only” category and 1 data point from “None”. Overall, samples from “S pool 1 only” were removed because without reliable S pool 2 data for these participants, we could not conclusively assign responses to “S pool 1 only” versus “S pool 1 \u0026amp; 2”.\u003c/p\u003e\u003cp\u003eWe fully removed panel 5e from Extended Data Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e5\u003c/a\u003e as it was based on what were previously considered pre-existing responses to S pool 2. Since we now know these are non-specific responses due to the contamination, the panel has been removed.\u003c/p\u003e\u003cp\u003eFor Extended Data Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e5\u003c/a\u003e, panel 5f (now 5e), we previously chose ELISpot examples that were from participants with a non-specific response to S pool 2. We have updated the revised figure to show a single example from a participant that had no such response.\u003c/p\u003e\u003cp\u003eThree panels within Extended Data Fig. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e7\u003c/a\u003e were revised: 7b, 7d and 7e. In panel 7b exploring the CD4\u003csup\u003e+\u003c/sup\u003e T-cell profiles, we removed 1 participant in the 20 µg dose group due to the non-specific response to S pool 2. In panel 7d, we removed data for 10 of 41 participants that showed non-specific CD8\u003csup\u003e+\u003c/sup\u003e T-cell responses to S pool 2. The values above the data points were also updated as these correspond to the mean fractions per dose cohort and were thus affected by the data removal. In the revised panel 7e, we removed data from 3 of 8 participants in the CD8\u003csup\u003e+\u003c/sup\u003e responses against S pool 2. The overall response kinetics shown in this figure remain unchanged.\u003c/p\u003e\u003cp\u003eThe figures have been updated. Text in Figs. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e2\u003c/a\u003e, \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e3\u003c/a\u003e and Extended Data Figs. \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e5\u003c/a\u003e, \u003ca data-track=\"click\" data-track-label=\"link\" data-track-action=\"supplementary material anchor\" href=\"https://www.nature.com/articles/s41586-025-09355-7#MOESM1\"\u003e7\u003c/a\u003e legends were updated, and the “Vaccine-induced T cell responses” and “Polarization of T cell responses” sections have been updated, while the fourth paragraph of the original Discussion (and citations to original refs. 35,36) has been removed. For comparison, the original figure panels are available as Supplementary Information alongside the online version of this amendment. The changes have been made to the HTML and PDF versions of the article.\u003c/p\u003e\n                    \n                \u003c/div\u003e\u003cdiv\u003e\n                \u003cdiv id=\"author-information-section\" aria-labelledby=\"author-information\" data-title=\"Author information\"\u003e\u003ch2 id=\"author-information\"\u003eAuthor information\u003c/h2\u003e\u003cdiv id=\"author-information-content\"\u003e\u003ch3 id=\"affiliations\"\u003eAuthors and Affiliations\u003c/h3\u003e\u003col\u003e\u003cli id=\"Aff1\"\u003e\u003cp\u003eBioNTech, Mainz, Germany\u003c/p\u003e\u003cp\u003eUğur Şahin, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz, Mathias Vormehr, Jasmin Quandt, Nicole Bidmon, Alexander Ulges, Daniel Maurus, Sebastian Brachtendorf, Verena Lörks, Julian Sikorski, Peter Koch, Rolf Hilker, Dirk Becker, Ann-Kathrin Eller, Jan Grützner, Manuel Tonigold, Carsten Boesler, Corinna Rosenbaum, Ludwig Heesen, Marie-Cristine Kühnle, Ulrich Luxemburger, Alexandra Kemmer-Brück, David Langer, Stefanie Bolte, Tania Palanche, Azita J. Mahiny, Gábor Boros, Jonas Reinholz, Gábor T. Szabó, Katalin Karikó \u0026amp; Özlem Türeci\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff2\"\u003e\u003cp\u003eTRON gGmbH – Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany\u003c/p\u003e\u003cp\u003eUğur Şahin\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff3\"\u003e\u003cp\u003eRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA\u003c/p\u003e\u003cp\u003eAlina Baum, Kristen E. Pascal \u0026amp; Christos A. Kyratsous\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff4\"\u003e\u003cp\u003eBioNTech US, Cambridge, MA, USA\u003c/p\u003e\u003cp\u003eAsaf Poran \u0026amp; Jesse Z. Dong\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff5\"\u003e\u003cp\u003eBexon Clinical Consulting LLC, Upper Montclair, NJ, USA\u003c/p\u003e\u003cp\u003eMartin Bexon\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff6\"\u003e\u003cp\u003eCRS Clinical Research Services Mannheim GmbH, Mannheim, Germany\u003c/p\u003e\u003cp\u003eArmin Schultz\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff7\"\u003e\u003cp\u003eCRS Clinical Research Services Berlin GmbH, Berlin, Germany\u003c/p\u003e\u003cp\u003eSybille Baumann\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff8\"\u003e\u003cp\u003eUniversity of Texas Medical Branch, Galveston, TX, USA\u003c/p\u003e\u003cp\u003ePei-Yong Shi \u0026amp; Camila Fontes-Garfias\u003c/p\u003e\u003c/li\u003e\u003cli id=\"Aff9\"\u003e\u003cp\u003ePfizer, Pearl River, NY, US\u003c/p\u003e\u003cp\u003eJohn L. Perez, Mark Cutler, David Cooper, Philip R. Dormitzer \u0026amp; Kathrin U. Jansen\u003c/p\u003e\u003c/li\u003e\u003c/ol\u003e\u003cdiv data-test=\"author-info\"\u003e\u003cp\u003e\u003cspan\u003eAuthors\u003c/span\u003e\u003c/p\u003e\u003col\u003e\u003cli id=\"auth-U_ur-_ahin-Aff1-Aff2\"\u003e\u003cspan\u003eUğur Şahin\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Alexander-Muik-Aff1\"\u003e\u003cspan\u003eAlexander Muik\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Isabel-Vogler-Aff1\"\u003e\u003cspan\u003eIsabel Vogler\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Evelyna-Derhovanessian-Aff1\"\u003e\u003cspan\u003eEvelyna Derhovanessian\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Lena_M_-Kranz-Aff1\"\u003e\u003cspan\u003eLena M. Kranz\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Mathias-Vormehr-Aff1\"\u003e\u003cspan\u003eMathias Vormehr\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Jasmin-Quandt-Aff1\"\u003e\u003cspan\u003eJasmin Quandt\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Nicole-Bidmon-Aff1\"\u003e\u003cspan\u003eNicole Bidmon\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Alexander-Ulges-Aff1\"\u003e\u003cspan\u003eAlexander Ulges\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Alina-Baum-Aff3\"\u003e\u003cspan\u003eAlina Baum\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Kristen_E_-Pascal-Aff3\"\u003e\u003cspan\u003eKristen E. Pascal\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Daniel-Maurus-Aff1\"\u003e\u003cspan\u003eDaniel Maurus\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Sebastian-Brachtendorf-Aff1\"\u003e\u003cspan\u003eSebastian Brachtendorf\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Verena-L_rks-Aff1\"\u003e\u003cspan\u003eVerena Lörks\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Julian-Sikorski-Aff1\"\u003e\u003cspan\u003eJulian Sikorski\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Peter-Koch-Aff1\"\u003e\u003cspan\u003ePeter Koch\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Rolf-Hilker-Aff1\"\u003e\u003cspan\u003eRolf Hilker\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Dirk-Becker-Aff1\"\u003e\u003cspan\u003eDirk Becker\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Ann_Kathrin-Eller-Aff1\"\u003e\u003cspan\u003eAnn-Kathrin Eller\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Jan-Gr_tzner-Aff1\"\u003e\u003cspan\u003eJan Grützner\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Manuel-Tonigold-Aff1\"\u003e\u003cspan\u003eManuel Tonigold\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Carsten-Boesler-Aff1\"\u003e\u003cspan\u003eCarsten Boesler\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Corinna-Rosenbaum-Aff1\"\u003e\u003cspan\u003eCorinna Rosenbaum\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Ludwig-Heesen-Aff1\"\u003e\u003cspan\u003eLudwig Heesen\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Marie_Cristine-K_hnle-Aff1\"\u003e\u003cspan\u003eMarie-Cristine Kühnle\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Asaf-Poran-Aff4\"\u003e\u003cspan\u003eAsaf Poran\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Jesse_Z_-Dong-Aff4\"\u003e\u003cspan\u003eJesse Z. Dong\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Ulrich-Luxemburger-Aff1\"\u003e\u003cspan\u003eUlrich Luxemburger\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Alexandra-Kemmer_Br_ck-Aff1\"\u003e\u003cspan\u003eAlexandra Kemmer-Brück\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-David-Langer-Aff1\"\u003e\u003cspan\u003eDavid Langer\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Martin-Bexon-Aff5\"\u003e\u003cspan\u003eMartin Bexon\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Stefanie-Bolte-Aff1\"\u003e\u003cspan\u003eStefanie Bolte\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Tania-Palanche-Aff1\"\u003e\u003cspan\u003eTania Palanche\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Armin-Schultz-Aff6\"\u003e\u003cspan\u003eArmin Schultz\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Sybille-Baumann-Aff7\"\u003e\u003cspan\u003eSybille Baumann\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Azita_J_-Mahiny-Aff1\"\u003e\u003cspan\u003eAzita J. Mahiny\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-G_bor-Boros-Aff1\"\u003e\u003cspan\u003eGábor Boros\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Jonas-Reinholz-Aff1\"\u003e\u003cspan\u003eJonas Reinholz\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-G_bor_T_-Szab_-Aff1\"\u003e\u003cspan\u003eGábor T. Szabó\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Katalin-Karik_-Aff1\"\u003e\u003cspan\u003eKatalin Karikó\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Pei_Yong-Shi-Aff8\"\u003e\u003cspan\u003ePei-Yong Shi\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Camila-Fontes_Garfias-Aff8\"\u003e\u003cspan\u003eCamila Fontes-Garfias\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-John_L_-Perez-Aff9\"\u003e\u003cspan\u003eJohn L. Perez\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Mark-Cutler-Aff9\"\u003e\u003cspan\u003eMark Cutler\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-David-Cooper-Aff9\"\u003e\u003cspan\u003eDavid Cooper\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Christos_A_-Kyratsous-Aff3\"\u003e\u003cspan\u003eChristos A. Kyratsous\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Philip_R_-Dormitzer-Aff9\"\u003e\u003cspan\u003ePhilip R. Dormitzer\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-Kathrin_U_-Jansen-Aff9\"\u003e\u003cspan\u003eKathrin U. Jansen\u003c/span\u003e\u003c/li\u003e\u003cli id=\"auth-_zlem-T_reci-Aff1\"\u003e\u003cspan\u003eÖzlem Türeci\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e\u003c/div\u003e\u003ch3 id=\"corresponding-author\"\u003eCorresponding author\u003c/h3\u003e\u003cp id=\"corresponding-author-list\"\u003eCorrespondence to\n                \u003ca id=\"corresp-c1\" href=\"mailto:Ugur.Sahin@biontech.de\"\u003eUğur Şahin\u003c/a\u003e.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Sec1-section\" data-title=\"Supplementary information\"\u003e\u003ch2 id=\"Sec1\"\u003eSupplementary information\u003c/h2\u003e\u003c/div\u003e\u003cdiv id=\"rightslink-section\" data-title=\"Rights and permissions\"\u003e\u003ch2 id=\"rightslink\"\u003eRights and permissions\u003c/h2\u003e\u003c/div\u003e\u003cdiv id=\"article-info-section\" aria-labelledby=\"article-info\" data-title=\"About this article\"\u003e\u003ch2 id=\"article-info\"\u003eAbout this article\u003c/h2\u003e\u003cdiv id=\"article-info-content\"\u003e\u003cp\u003e\u003ca data-crossmark=\"10.1038/s41586-025-09355-7\" target=\"_blank\" rel=\"noopener\" href=\"https://crossmark.crossref.org/dialog/?doi=10.1038/s41586-025-09355-7\" data-track=\"click\" data-track-action=\"Click Crossmark\" data-track-label=\"link\" data-test=\"crossmark\"\u003e\u003cimg loading=\"lazy\" width=\"57\" height=\"81\" alt=\"Check for updates. Verify currency and authenticity via CrossMark\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\"/\u003e\u003c/a\u003e\u003c/p\u003e\u003cdiv\u003e\u003ch3 id=\"citeas\"\u003eCite this article\u003c/h3\u003e\u003cp\u003eŞahin, U., Muik, A., Vogler, I. \u003ci\u003eet al.\u003c/i\u003e Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.\n                    \u003ci\u003eNature\u003c/i\u003e  (2025). https://doi.org/10.1038/s41586-025-09355-7\u003c/p\u003e\u003cp\u003e\u003ca data-test=\"citation-link\" data-track=\"click\" data-track-action=\"download article citation\" data-track-label=\"link\" data-track-external=\"\" rel=\"nofollow\" href=\"https://citation-needed.springer.com/v2/references/10.1038/s41586-025-09355-7?format=refman\u0026amp;flavour=citation\"\u003eDownload citation\u003c/a\u003e\u003c/p\u003e\u003cul data-test=\"publication-history\"\u003e\u003cli\u003e\u003cp\u003ePublished\u003cspan\u003e: \u003c/span\u003e\u003cspan\u003e\u003ctime datetime=\"2025-07-16\"\u003e16 July 2025\u003c/time\u003e\u003c/span\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cabbr title=\"Digital Object Identifier\"\u003eDOI\u003c/abbr\u003e\u003cspan\u003e: \u003c/span\u003e\u003cspan\u003ehttps://doi.org/10.1038/s41586-025-09355-7\u003c/span\u003e\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\n            \u003c/div\u003e\u003c/div\u003e",
  "readingTime": "8 min read",
  "publishedTime": null,
  "modifiedTime": null
}
